Edwards Lifesciences Corp (EW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Edwards Lifesciences Corp (EW) has a cash flow conversion efficiency ratio of 0.004x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($43.80 Million) by net assets ($10.33 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EW net asset quality score to measure how much of total assets are equity-financed.
Edwards Lifesciences Corp - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Edwards Lifesciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Edwards Lifesciences Corp (EW) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Edwards Lifesciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edwards Lifesciences Corp ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
N/A |
|
Old Dominion Freight Line Inc
NASDAQ:ODFL
|
0.085x |
|
Nasdaq Inc
NASDAQ:NDAQ
|
0.051x |
|
Nan Ya Plastics Corp
TW:1303
|
0.000x |
|
MERCEDES-BENZ GRP ADR/1/4
F:DAII
|
0.029x |
|
Crowdstrike Holdings Inc
NASDAQ:CRWD
|
0.111x |
|
Ambev S.A.
SA:ABEV3
|
0.035x |
|
Shengyi Technology Co Ltd
SHG:600183
|
0.061x |
Annual Cash Flow Conversion Efficiency for Edwards Lifesciences Corp (1999–2025)
The table below shows the annual cash flow conversion efficiency of Edwards Lifesciences Corp from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see EW market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.34 Billion | $1.60 Billion | 0.154x | +186.34% |
| 2024-12-31 | $10.06 Billion | $542.30 Million | 0.054x | -59.58% |
| 2023-12-31 | $6.72 Billion | $895.80 Million | 0.133x | -36.45% |
| 2022-12-31 | $5.81 Billion | $1.22 Billion | 0.210x | -29.32% |
| 2021-12-31 | $5.84 Billion | $1.73 Billion | 0.297x | +28.77% |
| 2020-12-31 | $4.57 Billion | $1.05 Billion | 0.230x | -18.93% |
| 2019-12-31 | $4.15 Billion | $1.18 Billion | 0.284x | -3.66% |
| 2018-12-31 | $3.14 Billion | $926.80 Million | 0.295x | -11.68% |
| 2017-12-31 | $2.99 Billion | $1.00 Billion | 0.334x | +24.24% |
| 2016-12-31 | $2.62 Billion | $704.40 Million | 0.269x | +22.47% |
| 2015-12-31 | $2.50 Billion | $549.70 Million | 0.220x | -52.92% |
| 2014-12-31 | $2.19 Billion | $1.02 Billion | 0.467x | +53.88% |
| 2013-12-31 | $1.56 Billion | $472.70 Million | 0.303x | +19.98% |
| 2012-12-31 | $1.48 Billion | $373.80 Million | 0.253x | +7.49% |
| 2011-12-31 | $1.34 Billion | $314.50 Million | 0.235x | +22.32% |
| 2010-12-31 | $1.31 Billion | $251.40 Million | 0.192x | +34.61% |
| 2009-12-31 | $1.16 Billion | $165.30 Million | 0.143x | -18.11% |
| 2008-12-31 | $878.80 Million | $153.20 Million | 0.174x | -30.75% |
| 2007-12-31 | $835.00 Million | $210.20 Million | 0.252x | -18.26% |
| 2006-12-31 | $749.40 Million | $230.80 Million | 0.308x | +55.34% |
| 2005-12-31 | $690.00 Million | $136.80 Million | 0.198x | -31.05% |
| 2004-12-31 | $628.10 Million | $180.60 Million | 0.288x | +49.32% |
| 2003-12-31 | $635.10 Million | $122.30 Million | 0.193x | -13.87% |
| 2002-12-31 | $539.40 Million | $120.60 Million | 0.224x | +1.61% |
| 2001-12-31 | $459.00 Million | $101.00 Million | 0.220x | -29.33% |
| 2000-12-31 | $440.00 Million | $137.00 Million | 0.311x | +116.54% |
| 1999-12-31 | $1.22 Billion | $176.00 Million | 0.144x | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more